Related Experiment Video
Updated: Jul 10, 2026
Differentiation of Human Pluripotent Stem Cells Into Pancreatic Beta-Cell Precursors in a 2D Culture System
Published on: December 16, 2021
Pathway decision-making strategies for generating pancreatic beta-cells: systems biology or hit and miss?
1Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Aurora, Colorado, USA. jan.jensen@uchsc.edu
Purpose Of Review:
Method selection strategies to achieve beta-cell differentiation from human embryonic stem cells are reviewed.
Recent Findings:
Expectations are high for an embryonic stem cell derived cellular replacement method to cure diabetes, and recent observations indicate that mature beta-cells can be derived from human embryonic stem cells. In terms of the translational setting, however, we are not there yet; conversion of embryonic stem cells to fully mature beta-cells is not effective and does not provide an exclusive beta-cell population as the end-product.
Summary:
Studies emphasize that expecting development of a 'magic media bullet' that promotes endocrine fate is rather optimistic; consecutive administration of signaling inducers, carefully provided to mimic normal development, is more likely to succeed. To accomplish this task we need better understanding of the extracellular signaling pathways that drive progressive endodermal fate choices throughout development. Knowledge of cell-intrinsic control of fate assignments in pancreas is growing rapidly. Nevertheless, insufficient information regarding morphogen codes that operate in endoderm and pancreas is hindering development of better, directed differentiation schema of uncommitted embryonic stem cells toward endodermal, pancreatic, and subsequent endocrine specific fates. A systematic approach to defining morphogen codes in developing endoderm and pancreas appears timely and justified.
Insights
Generating functional beta-cells from human embryonic stem cells for diabetes treatment is challenging. Current methods are ineffective, requiring a deeper understanding of developmental signaling for successful beta-cell differentiation.
Area of Science:
- Developmental Biology
- Stem Cell Biology
- Endocrinology
Background:
- Human embryonic stem cells (hESCs) hold promise for regenerative medicine, particularly for treating diabetes.
- Beta-cell replacement therapy is a potential cure for diabetes, aiming to restore insulin production.
Purpose of the Study:
- To review method selection strategies for beta-cell differentiation from hESCs.
- To assess the current status and challenges in deriving mature, functional beta-cells from hESCs for therapeutic applications.
Main Methods:
- Review of existing literature on hESC differentiation protocols.
- Analysis of signaling pathways and morphogen codes involved in endodermal and pancreatic development.
Main Results:
- Recent advances show mature beta-cells can be derived from hESCs, but current methods are not translationally effective.
- Differentiation protocols often yield mixed cell populations and lack full beta-cell maturation.
Conclusions:
- A 'magic media bullet' is unlikely; sequential signaling induction mimicking natural development is crucial.
- A better understanding of extracellular signaling and morphogen codes in endoderm and pancreas development is needed.
- Systematic definition of these codes is essential for developing improved directed differentiation strategies for hESCs.
